Use of recombinant IL-2 (RU49637) after autologous bone marrow transplantation (BMT) in patients with hematological neoplasias: a phase 1 study.

Blaise, D

Use of recombinant IL-2 (RU49637) after autologous bone marrow transplantation (BMT) in patients with hematological neoplasias: a phase 1 study. [electronic resource] - Bone marrow transplantation 1991 - 146 p. digital

Publication Type: Clinical Trial; Journal Article; Multicenter Study

0268-3369


Bone Marrow Transplantation
Combined Modality Therapy
Drug Evaluation
Humans
Immunologic Factors--therapeutic use
Interleukin-2--therapeutic use
Leukemia--immunology
Lymphoma--immunology
Recombinant Proteins--therapeutic use
Transplantation, Autologous